EF Hutton Starts Lumos Pharma (LUMO) at Buy

EF Hutton analyst Jason Kolbert initiates coverage on Lumos Pharma (NASDAQ: LUMO) with a Buy rating and a price target of $16.00.

The analyst comments "We model multiple indications. We apply a Probability of Success factor for each indication of 70% and a 30% discount rate (r). We assume additional capital will be raised in our final share count. We then apply these projections to our Free Cash Flow to the firm, or FCFF discounted EPS or dEPS, and sum-of-the-parts or SOP models, which are equal-weighted, averaged, and rounded to the nearest whole number to derive our 12-month price target of $16.00."

For an analyst ratings summary and ratings history on Lumos Pharma click here. For more ratings news on Lumos Pharma click here.

Shares of Lumos Pharma closed at $3.76 yesterday.

You May Also Be Interested In

• Chevron signed an agreement with Iraq's Basra Oil Company to advance commercial negotiations for West Qurna 2
• Boxabl completes SPAC merger, begins trading on Nasdaq at $3.5B value
• Trump: I asked Darline Graham to run for U.S. senate in special Republican primary on Tuesday, August 11